Ubs Group Ag Lava Therapeutics Nv Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Ubs Group Ag holds 1,072 shares of LVTX stock, worth $1,093. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,072

Holding current value

$1,093

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.57 - $2.29 $1,683 - $2,454	1,072 New	1,072 $1,000
Q1 2024 May 13, 2024	BUY	$1.53 - $4.03 $13,739 - $36,189	8,980 New	8,980 $29,000
Q1 2023 May 12, 2023	BUY	$1.59 - $3.97 $4,919 - $12,283	3,094 Added 309.09%	4,095 $6,000
Q4 2022 Feb 08, 2023	BUY	$3.37 - $7.31 $3,373 - $7,317	1,001 New	1,001 $3,000
Q2 2022 Aug 10, 2022	SELL	$2.28 - $4.4 $1,869 - $3,608	-820 Reduced 66.88%	406 $1,000
Q1 2022 May 16, 2022	SELL	$4.28 - $6.55 $2,238 - $3,425	-523 Reduced 29.9%	1,226 $5,000
Q4 2021 Feb 14, 2022	BUY	$4.23 - $7.77 $7,398 - $13,589	1,749 New	1,749 $10,000

Others Institutions Holding LVTX

# of Institutions

Shares Held

3.61M

Call Options Held

32.9K

Put Options Held

500

View Full List

About LAVA Therapeutics NV

Ticker LVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,797,700
Market Cap $26.3M
Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...

More about LVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account